pd 173074 has been researched along with Lung Neoplasms in 12 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lung cancer is the leading cause of cancer-related deaths across the world." | 1.46 | Drug-sensitive FGFR3 mutations in lung adenocarcinoma. ( Aich, J; Chandna, P; Chandrani, P; Chaudhari, P; Choughule, A; Dhamne, H; Dutt, A; Ingle, A; Iyer, DN; Iyer, P; Joshi, A; Karpe, A; Kumar, R; Mohanty, B; Noronha, V; Patil, V; Prabhash, K; Prasad, R; Ramaswamy, A; Ranjan, M; Sethunath, V; Thorat, R; Upadhyay, P, 2017) |
| "Arsenic trioxide (ATO) was previously shown to suppress growth of lung cancer." | 1.43 | Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma. ( Ho, JC; Lam, SK; Leung, LL; Li, YY; Zheng, CY, 2016) |
| "Lung cancer is the commonest cancer killer." | 1.35 | The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. ( Aboagye, EO; Jeffery, RE; Latigo, J; Lemoine, NR; Nye, E; Pardo, OE; Poulsom, R; Seckl, MJ; Spencer-Dene, B; Stamp, GW, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Terai, H | 1 |
| Soejima, K | 1 |
| Yasuda, H | 1 |
| Nakayama, S | 1 |
| Hamamoto, J | 1 |
| Arai, D | 1 |
| Ishioka, K | 1 |
| Ohgino, K | 1 |
| Ikemura, S | 1 |
| Sato, T | 1 |
| Yoda, S | 1 |
| Satomi, R | 1 |
| Naoki, K | 1 |
| Betsuyaku, T | 1 |
| Qian, X | 1 |
| Anzovino, A | 1 |
| Kim, S | 1 |
| Suyama, K | 1 |
| Yao, J | 1 |
| Hulit, J | 1 |
| Agiostratidou, G | 1 |
| Chandiramani, N | 1 |
| McDaid, HM | 1 |
| Nagi, C | 1 |
| Cohen, HW | 1 |
| Phillips, GR | 1 |
| Norton, L | 1 |
| Hazan, RB | 1 |
| Thomas, A | 1 |
| Lee, JH | 1 |
| Abdullaev, Z | 1 |
| Park, KS | 1 |
| Pineda, M | 1 |
| Saidkhodjaeva, L | 1 |
| Miettinen, M | 1 |
| Wang, Y | 2 |
| Pack, SD | 1 |
| Giaccone, G | 1 |
| Lei, J | 1 |
| Li, W | 1 |
| Yang, Y | 1 |
| Lu, Q | 1 |
| Zhang, N | 1 |
| Bai, G | 1 |
| Zhong, D | 1 |
| Su, K | 1 |
| Liu, B | 1 |
| Li, X | 1 |
| Wang, X | 1 |
| Kotani, H | 1 |
| Ebi, H | 1 |
| Kitai, H | 1 |
| Nanjo, S | 1 |
| Kita, K | 1 |
| Huynh, TG | 1 |
| Ooi, A | 1 |
| Faber, AC | 1 |
| Mino-Kenudson, M | 1 |
| Yano, S | 1 |
| Lam, SK | 1 |
| Leung, LL | 1 |
| Li, YY | 1 |
| Zheng, CY | 1 |
| Ho, JC | 1 |
| Chandrani, P | 1 |
| Prabhash, K | 1 |
| Prasad, R | 1 |
| Sethunath, V | 1 |
| Ranjan, M | 1 |
| Iyer, P | 1 |
| Aich, J | 1 |
| Dhamne, H | 1 |
| Iyer, DN | 1 |
| Upadhyay, P | 1 |
| Mohanty, B | 1 |
| Chandna, P | 1 |
| Kumar, R | 1 |
| Joshi, A | 1 |
| Noronha, V | 1 |
| Patil, V | 1 |
| Ramaswamy, A | 1 |
| Karpe, A | 1 |
| Thorat, R | 1 |
| Chaudhari, P | 1 |
| Ingle, A | 1 |
| Choughule, A | 1 |
| Dutt, A | 1 |
| Thomson, S | 1 |
| Petti, F | 1 |
| Sujka-Kwok, I | 1 |
| Epstein, D | 1 |
| Haley, JD | 1 |
| Pardo, OE | 1 |
| Latigo, J | 1 |
| Jeffery, RE | 1 |
| Nye, E | 1 |
| Poulsom, R | 1 |
| Spencer-Dene, B | 1 |
| Lemoine, NR | 1 |
| Stamp, GW | 1 |
| Aboagye, EO | 1 |
| Seckl, MJ | 2 |
| Turner, NC | 1 |
| Weiss, J | 1 |
| Sos, ML | 1 |
| Seidel, D | 1 |
| Peifer, M | 1 |
| Zander, T | 1 |
| Heuckmann, JM | 1 |
| Ullrich, RT | 1 |
| Menon, R | 1 |
| Maier, S | 1 |
| Soltermann, A | 1 |
| Moch, H | 1 |
| Wagener, P | 1 |
| Fischer, F | 1 |
| Heynck, S | 1 |
| Koker, M | 1 |
| Schöttle, J | 1 |
| Leenders, F | 1 |
| Gabler, F | 1 |
| Dabow, I | 1 |
| Querings, S | 1 |
| Heukamp, LC | 1 |
| Balke-Want, H | 1 |
| Ansén, S | 1 |
| Rauh, D | 1 |
| Baessmann, I | 1 |
| Altmüller, J | 1 |
| Wainer, Z | 1 |
| Conron, M | 1 |
| Wright, G | 1 |
| Russell, P | 1 |
| Solomon, B | 1 |
| Brambilla, E | 1 |
| Brambilla, C | 1 |
| Lorimier, P | 1 |
| Sollberg, S | 1 |
| Brustugun, OT | 1 |
| Engel-Riedel, W | 1 |
| Ludwig, C | 1 |
| Petersen, I | 1 |
| Sänger, J | 1 |
| Clement, J | 1 |
| Groen, H | 1 |
| Timens, W | 1 |
| Sietsma, H | 1 |
| Thunnissen, E | 1 |
| Smit, E | 1 |
| Heideman, D | 1 |
| Cappuzzo, F | 1 |
| Ligorio, C | 1 |
| Damiani, S | 1 |
| Hallek, M | 1 |
| Beroukhim, R | 1 |
| Pao, W | 1 |
| Klebl, B | 1 |
| Baumann, M | 1 |
| Buettner, R | 1 |
| Ernestus, K | 1 |
| Stoelben, E | 1 |
| Wolf, J | 1 |
| Nürnberg, P | 1 |
| Perner, S | 1 |
| Thomas, RK | 1 |
| Oneyama, C | 1 |
| Ikeda, J | 1 |
| Okuzaki, D | 1 |
| Suzuki, K | 1 |
| Kanou, T | 1 |
| Shintani, Y | 1 |
| Morii, E | 1 |
| Okumura, M | 1 |
| Aozasa, K | 1 |
| Okada, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Therapeutic Trial of Afatinib in the Neoadjuvant Setting. Molecular Effects of Afatinib: A Window of Opportunity Trial In Early Stage NSCLC[NCT01480141] | Phase 2 | 0 participants (Actual) | Interventional | 2012-01-31 | Withdrawn (stopped due to PI left MUSC, no patient enrollments) | ||
| Study on Fluids Associated to Lung Cancer, of the Ectopic Expression of Cancer Testis Gene and Mutation as Diagnostics and Prognosis Biomarkers[NCT02853006] | 31 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| A Prospective Randomized Phase Ⅱ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer[NCT02577341] | Phase 2 | 122 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for pd 173074 and Lung Neoplasms
| Article | Year |
|---|---|
Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Topics: Apoptosis; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clone Cells; D | 2013 |
N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties.
Topics: Aldehyde Dehydrogenase; Animals; Benzamides; Breast Neoplasms; Cadherins; Cell Movement; Cell Prolif | 2014 |
Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
Topics: Blotting, Western; Cell Proliferation; Chromosomes, Human, Pair 8; Comparative Genomic Hybridization | 2014 |
TC-1 overexpression promotes cell proliferation in human non-small cell lung cancer that can be inhibited by PD173074.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; C | 2014 |
Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Gene Ampli | 2016 |
Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell L | 2016 |
Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Animals; Cell Proliferation; Drug Resistance, N | 2017 |
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatography, Liquid; Drug Res | 2008 |
The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Cisplatin; Drug Resistance, N | 2009 |
A therapeutic target for smoking-associated lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small- | 2010 |
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small- | 2010 |
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small- | 2010 |
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small- | 2010 |
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small- | 2010 |
MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
Topics: Animals; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Cluster An | 2011 |